Yale Depression Research Program
Psychiatry
Dr. Gerard Sanacora, MD
|
|
Give Review
Gerard Sanacora, MD works in the field of Psychiatry. He researched medicine at Stony Brook University School of Medicine. He has 2 awards "America's Top Doctors" and "Top Doctors: New York Metro Area". Gerard Sanacora is a published doctor. He has 76 publications published. The most current publication "Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission ..."
Publications
- A history of early life parental loss or separation is associated with successful cognitive-behavioral therapy in major depressive disorder.
- Regulation of extrasynaptic glutamate levels as a pathophysiological mechanism in disorders of motivation and addiction.
- Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders?
- In Vivo Ketamine-Induced Changes in [(11)C]ABP688 Binding to Metabotropic Glutamate Receptor Subtype 5.
- Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects.
- Glial abnormalities in substance use disorders and depression: Does shared glutamatergic dysfunction contribute to comorbidity?
- Scopolamine Rapidly Increases Mammalian Target Of Rapamycin Complex 1 Signaling, Synaptogenesis, and Antidepressant Behavioral Responses.
- From pathophysiology to novel antidepressant drugs: glial contributions to the pathology and treatment of mood disorders.
- Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond.
- Effects of Ketamine in Treatment-Refractory Obsessive-Compulsive Disorder.
- ¹H-[¹³C]-nuclear magnetic resonance spectroscopy measures of ketamine's effect on amino acid neurotransmitter metabolism.
- Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics.
- Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole.
- Developmental aspect of differences in hypothalamic preproneuropeptide y messenger ribonucleic Acid content in lean and genetically obese zucker rats.
- Current perspectives on the pathophysiology of schizophrenia, depression, and anxiety disorders.
- ECS-Induced mossy fiber sprouting and BDNF expression are attenuated by ketamine pretreatment.
- Impairment of GABAergic transmission in depression: new insights from neuroimaging studies.
- A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression.
- Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy.
- Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission ...
- The need for outcome studies.
- Increased hypothalamic content of preproneuropeptide Y messenger ribonucleic acid in genetically obese Zucker rats and its regulation by food deprivation.
- Inhibition of hypothalamic neuropeptide Y gene expression by insulin.
- Joint analysis of repeatedly observed continuous and ordinal measures of disease severity.
- Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments.
- Elevated cerebrospinal fluid substance p concentrations in posttraumatic stress disorder and major depression.
- Beyond monoamines: glutamatergic function in mood disorders.
- N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder.
- The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission.
- The roles of glutamate receptors across major neurological and psychiatric disorders.
- Overview of glutamatergic neurotransmission in the nervous system.
- Intravenous ethanol infusion decreases human cortical ?-aminobutyric acid and N-acetylaspartate as measured with proton magnetic resonance spectroscopy at 4 tesla.
- Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders.
- Antidepressant-like properties of oral riluzole and utility of incentive disengagement models of depression in mice.
- Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors.
- Monoamine depletion in unmedicated depressed subjects.
- Genotype-controlled analysis of plasma dopamine beta-hydroxylase activity in psychotic unipolar major depression.
- Sex differences in diencephalon serotonin transporter availability in major depression.
- Cortical gamma-aminobutyric acid concentrations in depressed patients receiving cognitive behavioral therapy.
- Antidepressant effect of ketamine during ECT.
- Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.
- Sex, GABA, and nicotine: the impact of smoking on cortical GABA levels across the menstrual cycle as measured with proton magnetic resonance spectroscopy.
- Riluzole augmentation for treatment-resistant depression.
- Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors.
- Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression.
- Addition of the alpha2-antagonist yohimbine to fluoxetine: effects on rate of antidepressant response.
- Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial.
- Clinical studies implementing glutamate neurotransmission in mood disorders.
- Mutation screen of the glutamate decarboxylase-67 gene and haplotype association to unipolar depression.
- Cerebral benzodiazepine receptors in depressed patients measured with [123I]iomazenil SPECT.
- Increased cortical GABA concentrations in depressed patients receiving ECT.
- Association of polymorphisms in HCN4 with mood disorders and obsessive compulsive disorder.
- The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS.
- Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial.
- Computerized ambulatory monitoring in mood disorders: feasibility, compliance, and reactivity.
- Cortical inhibition, gamma-aminobutyric acid, and major depression: there is plenty of smoke but is there fire?
- Do glutamatergic agents represent a new class of antidepressant drugs? Part 2.
- Reduced density of calbindin immunoreactive GABAergic neurons in the occipital cortex in major depression: relevance to neuroimaging studies.
- Do glutamatergic agents represent a new class of antidepressant drugs? Part 1.
- Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia.
- Targeting glial physiology and glutamate cycling in the treatment of depression.
- New understanding of mechanisms of action of bipolar medications.
- Reviewing medications for bipolar disorder: understanding the mechanisms of action.
- Major depression: emerging therapeutics.
- Riluzole in the treatment of mood and anxiety disorders.
- Chronic riluzole treatment increases glucose metabolism in rat prefrontal cortex and hippocampus.
- Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications.
- Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders.
- It is time to take a stand for medical research and against terrorism targeting medical scientists.
- GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action.
- The NMDA receptor as a therapeutic target in major depressive disorder.
- Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms.
- Can cognitive behavioral therapy reduce relapse rates of depression after ECT? a preliminary study.
- Antidepressant-like effects of ceftriaxone in male C57BL/6J mice.
- Visual hallucinations from the addition of riluzole to memantine and bupropion.
Schools
State University of New York Health Science Center At Stony Brook
Yale New Haven Hospital
Doctors Specialties
- Psychiatry
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors: New York Metro Area
Education
-
Yale-New Haven Hospital -
Stony Brook University School of Medicine
Hospital
-
Yale-New Haven Hospital
Helpful Reviews
Similar Doctors
|
|
Dr. Rochelle R. Schreibman, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Oscar F. Hills, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael A. Nelken, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrew L. Balter, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jonas P. Hannestad, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marina Nakic, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Susan V. Lewis, MD |
|
|
Dr. Cynthia N. Wilson, MD |
|
|
Dr. Carolyn C. Kovel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Julie E. Peters, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Borislav Meandzija, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jose G. Bejarano, MD |
|
|
Dr. Neil B. Bruce, MD |
|
|
Dr. Patrice J. Holmes, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sara Rubin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ashleigh Colin, MD |